Nutriband (NTRB) Competitors

Nutriband has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

CVRx has a net margin of -89.14% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat CVRx's return on equity.

CVRx presently has a consensus target price of $11.50, indicating a potential upside of 109.09%. Given CVRx's stronger consensus rating and higher possible upside, equities analysts clearly believe CVRx is more favorable than Nutriband.

75.3% of CVRx shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 16.6% of CVRx shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, CVRx had 5 more articles in the media than Nutriband. MarketBeat recorded 5 mentions for CVRx and 0 mentions for Nutriband. CVRx's average media sentiment score of 0.75 beat Nutriband's score of 0.00 indicating that CVRx is being referred to more favorably in the media.

CVRx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Fractyl Health has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Fractyl Health currently has a consensus price target of $5.12, suggesting a potential upside of 656.05%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts plainly believe Fractyl Health is more favorable than Nutriband.

In the previous week, Fractyl Health had 2 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Fractyl Health and 0 mentions for Nutriband. Nutriband's average media sentiment score of 0.00 beat Fractyl Health's score of -0.10 indicating that Nutriband is being referred to more favorably in the news media.

Nutriband has higher revenue and earnings than Fractyl Health. Nutriband is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Fractyl Health has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat Fractyl Health's return on equity.

19.7% of Nutriband shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neuronetics has a consensus target price of $4.00, indicating a potential upside of 85.19%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Nutriband.

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neuronetics has a net margin of -24.48% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat Neuronetics' return on equity.

In the previous week, Neuronetics had 7 more articles in the media than Nutriband. MarketBeat recorded 7 mentions for Neuronetics and 0 mentions for Nutriband. Neuronetics' average media sentiment score of 0.83 beat Nutriband's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media.

Nutriband has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Nutriband has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Microbot Medical currently has a consensus price target of $6.63, indicating a potential upside of 274.29%. Given Microbot Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than Nutriband.

Nutriband has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

In the previous week, Microbot Medical had 1 more articles in the media than Nutriband. MarketBeat recorded 1 mentions for Microbot Medical and 0 mentions for Nutriband. Microbot Medical's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Microbot Medical has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Microbot Medical's return on equity of -21.84% beat Nutriband's return on equity.

Microbot Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.